Company intelligence / Profile preview

Jing Medicine Technology Shanghai Ltd.

Shanghai, Shanghai, Chinajingmedicine.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Jing Medicine Technology Shanghai Ltd. develops small molecule drugs using a proprietary protein degradation platform, including PROTACs. Their lead asset, HJM‑561, selectively degrades EGFR C797S triple mutants and shows strong preclinical antitumor activity in NSCLC models resistant to osimertinib. The company leverages a bacteriophage database and advanced protein targeting technologies. At least one clinical trial has been initiated.

Therapeutic areas: Oncology
Modalities: Small moleculesPROTACs (Proteolysis Targeting Chimeras)Protein degradation technologyBacteriophage database (enabling technology)
Industry: Biotech

Drug pipeline

2 assets

HJ-004

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Jing Medicine Technology Shanghai Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jing Medicine Technology Shanghai Ltd..

Explore the full profile